Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's Why

Key Points

• Theravance Biopharma stock rose by 3.4%, reaching $12.84 during mid-day trading, with approximately 240,577 shares exchanged.
• Analysts have mixed outlooks, with BTIG Research raising its price target to $25.00 while Wall Street Zen downgraded the stock to a "hold" rating.
• The company's recent quarterly earnings beat expectations significantly, reporting $1.08 earnings per share and $26.20 million in revenue, exceeding analyst estimates.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s stock price was up 3.4% during mid-day trading on Thursday . The stock traded as high as $12.84 and last traded at $12.84. Approximately 240,577 shares changed hands during trading, a decline of 5% from the average daily volume of 253,079 shares. The stock had previously closed at $12.42.

Analysts Set New Price Targets

TBPH has been the topic of several research analyst reports. BTIG Research boosted their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Wall Street Zen lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a research note on Tuesday, June 17th.

Theravance Biopharma Trading Up 4.3%

The firm has a 50 day moving average price of $11.11 and a 200-day moving average price of $9.94. The firm has a market cap of $647.55 million, a price-to-earnings ratio of 54.27 and a beta of 0.01.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $1.20. The company had revenue of $26.20 million for the quarter, compared to analyst estimates of $16.04 million. Theravance Biopharma had a net margin of 16.88% and a return on equity of 7.41%. As a group, equities analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 24,000 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the transaction, the senior vice president owned 336,918 shares of the company's stock, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 44,000 shares of company stock valued at $491,800. Corporate insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently made changes to their positions in the business. Nuveen LLC purchased a new position in Theravance Biopharma during the 1st quarter valued at about $3,348,000. Newtyn Management LLC boosted its holdings in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after purchasing an additional 258,337 shares during the period. Jefferies Financial Group Inc. boosted its holdings in shares of Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock worth $3,054,000 after purchasing an additional 255,455 shares during the period. Acadian Asset Management LLC grew its position in Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after purchasing an additional 174,451 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Theravance Biopharma by 20.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after buying an additional 95,304 shares during the period. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.